Abstract
Disclosed herein is a technology to perform programmable RNA editing at single-nucleotide resolution using RNA-targeting CRISPR/Cas9. This approach, which Applicants have termed “Cas9-directed RNA editing” or “CREDIT,” provides a means to reversibly alter genetic information in a temporal manner, unlike traditional CRISPR/Cas9 driven genomic engineering which relies on permanently altering DNA sequence.
| Original language | English (US) |
|---|---|
| Patent number | US20230053915A1 |
| Priority date | 7/11/22 |
| Filing date | 7/11/22 |
| State | Published - Feb 23 2023 |
Fingerprint
Dive into the research topics of 'Directed editing of cellular rna via nuclear delivery of crispr/cas9'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS